EU Accelerated Assessment Tracker
Executive Summary
Will Chugai's European marketing authorization application for satralizumab be fast-tracked when the company files for approval? The European Medicines Agency's drug evaluation committee, the CHMP, will decide this week.
You may also be interested in...
Rivals Await CHMP Decisions On Drugs For NMOSD
The European Medicines Agency’s drug evaluation committee, the CHMP, is this week considering products from Alexion Pharmaceuticals and Roche/Chugai Pharmaceutical who are both vying for a share of the as yet untapped EU market for neuromyelitis optica spectrum disorder.
EU Accelerated Assessment – Hard To Get, Hard To Keep
It’s hard enough in the first place for companies to persuade the European Medicines Agency that their planned marketing authorization application should be fast-tracked. Many are also finding that after accelerated assessment is granted, it is taken away during the actual review.
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.